NEURAXIS INC

Company Overview

Neuraxis, Inc. is a growth‑stage medical technology company commercializing non‑implant auricular neuromodulation (PENFS) with a lead FDA de novo‑cleared product, IB‑Stim, sold primarily to children’s hospitals and pediatric clinics, plus a newly launched Rectal Expulsion Device (RED) for adults. The company emphasizes clinical evidence (700+ patients, randomized trials, a 292‑patient registry), KOL/society support, and payer engagement (Category III CPT now; transition to Category I planned for 2026). Operationally it is a small, vertically light organization (21 employees) with outsourced ISO‑13485 manufacturing, concentrated sales (three customers ~40–45% of revenue) and revenue tied to reimbursement adoption and FDA/510(k)/de novo timelines. Management reports modest revenue growth (FY2024 sales ~$2.69M; Q2 2025 sales ~$0.89M) but ongoing losses, improving cash from financings and a going‑concern auditor qualification tied to runway and future capital needs.

Executive Compensation Practices

Given its biotechnology/medical device profile and constrained cash runway, executive pay at Neuraxis is likely weighted toward equity and performance‑linked awards (options/RSUs and milestone bonuses) rather than high cash salaries; the company already recorded one‑time incentive program expenses in 2024 and increased G&A tied to being public. Key compensation drivers will be near‑term commercial and regulatory milestones: broader insurer reimbursement, transition to Category I CPT, FDA clearances/510(k) for new indications, RED uptake, and measurable revenue/volume growth across pediatric accounts. R&D progress, successful outsourced manufacturing continuity, and clinical data publication/KOL adoption will also be natural performance criteria for long‑term awards. The board may favor equity or milestone‑based payouts to conserve cash—increasing dilution risk for shareholders—while balancing retention for a small, specialized management team.

Insider Trading Considerations

Material nonpublic events that will strongly move the stock — and therefore be focal points for insider trading rules — include FDA decisions, CPT coding/payer policy announcements (Category I implementation in 2026), major insurer coverage wins, clinical data releases, and financing transactions (recent Series B preferred issuance and 2025 equity/warrant activity). Because the company has a small public float, concentrated revenue and insider holdings, and a history of financings, insider buys can signal confidence but insider sales may reflect liquidity needs after exercises or financings; monitor Form 4 filings and timing relative to announced financings. SOX 404 compliance, Section 16 reporting deadlines, blackout periods around earnings/FDA/payer events, and the likelihood that insiders use pre‑arranged 10b5‑1 plans are important compliance considerations for researchers and traders tracking executive activity.